Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma.
2017
The programmed death-1 (PD-1) pathway of immune evasion is exploited by many malignancies to limit host T-cell-mediated immune responses. Nivolumab is a PD-1-blocking monoclonal antibody that disrupts this pathway and is FDA approved for the treatment of metastatic melanoma, renal cell carcinoma, an
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
13
References
26
Citations
NaN
KQI